Menu
Press release
03/05/2023
DOMISANTE and IKI announce their partnership to offer a complete urinalysis solution for home nursing services (SSIAD) and home hospitalization (HAD) for :
DOMISANTE, a company with a mission and a subsidiary of Medical Devices Venture, aims to offer a generic prevention and monitoring base to support, from the home :
– Ageing well
– Chronic diseases
– Post-op
Faced with medical deserts, and in order to preserve patient comfort and reinforce prevention, and thus encourage follow-up from home under optimum conditions, DOMISANTE offers a solution that provides simple, personalized contact with healthcare professionals.
The solution is aimed at all those involved in homecare:
Thanks to the health gateway, patients can take and monitor their vital signs at home, and access teleconsultation and remote assistance services.
For further information: https://www.domisante.com/
IKI has developed a home health laboratory, called URIKI, for personalized medical monitoring through simple, portable and accurate urinalysis. Among other things, it enables the monitoring of lifestyle-related chronic illnesses such as chronic kidney disease and cardiovascular disease. To achieve this, it combines connected biological analysis tools, personalized monitoring and patient engagement tools. The solution is CE-marked (DM-DIV) and protected by patents.
Why urine?
Urine is a mine of information. There are over 3,000 urinary metabolites linked to more than 220 pathologies, but also to our health behaviours: nutrition, hydration, physical activity, etc. This analysis is more easily integrated into a patient’s daily life than a blood test, because it is non-invasive and is based on a gesture (urinating) that we do naturally several times a day.
IKI’s challenge was to integrate this analysis into the daily lives of mobile patients and healthcare professionals, thanks to the portability and connectivity of its URIKI reader.
DOMISANTE and IKI share the same objective: to make the patient a player in his or her own health. Prevention is also a major focus for both companies.
URIKI’s portability for home care and monitoring, coupled with its specific urinary biomarkers, fits perfectly into the global approach proposed by DOMISANTE. URIKI will be accessible to patients via the DOMISANTE platform. What’s more, the data gathered by URIKI will enhance DOMISANTE’s offer in terms of detecting weak signals and patient profiles, with a view to early diagnosis and personalized follow-up.
DOMISANTE and IKI will be developing a joint offering for home care and monitoring, in response to strong market demand for the convergence of e-health solutions.
About Medical Devices Venture
ARCHOS subsidiary Medical Devices Venture is a holding company developing a portfolio of investments in Med Tech start-ups. The aim is to combine the expertise of hospital and university researchers with the Group’s industrialization, certification and marketing capabilities. Medical Devices Venture is listed on the Euronext Access + Paris market. ISIN: FR0014006PT9 – mnemo: MLMDV
For further information: www.medicaldevicesventure.com